US healthcare private equity rollup at the antitrust inflection: physician practices, hospital chapter 11, and the 2026 refi wall

Deal flow after the 2021 peak #

Pitchbook annual healthcare PE reports, summarized in industry coverage, place 2021 healthcare deal value near 151 billion dollars across roughly 1,400 transactions, the post pandemic high. Volume retraced as rates climbed. Pitchbook reported 2023 healthcare PE deal value near 88 billion dollars across about 1,000 deals, and 2024 came in near 115 billion dollars across roughly 1,049 deals as megadeals such as Walgreens VillageMD restructuring and several payer adjacent transactions lifted aggregate value while sponsor backed physician platforms slowed sharply. The first three quarters of 2025 ran on pace with 2024 in count but with smaller average deal size, consistent with a market that is still digesting 2021 and 2022 vintage capital structures.

Three forces shape the 2026 environment. Cost of capital has reset. Term loan B all in yields for healthcare LBOs ran 9 to 12 percent through 2024 per S and P Leveraged Commentary and Data, against 6 to 8 percent in the 2020 to 2021 vintage. Reimbursement compression has tightened operating margins, especially for anesthesia, emergency medicine, and radiology where the No Surprises Act has squeezed pricing power. Antitrust posture has turned. The FTC complaint against USAP and Welsh Carson in September 2023 and the revised HSR rule effective February 2025 have raised the bar on rollup disclosure. The result is a market that is still active, still concentrated in five to seven specialties, but on tighter underwriting and shorter hold expectations.

The rollup map by specialty #

PE consolidation in physician services concentrates in specialties with three properties. High Medicare and commercial mix, sufficient ancillary revenue such as ambulatory surgery centers, pathology, and imaging, and labor markets where employed physicians can be substituted for partner equity over time. Anesthesiology, dermatology, gastroenterology, ophthalmology, urology, cardiology, and OB GYN dominate the list. A 2023 study by Singh, Song, and Polsky in Health Affairs documented PE acquisition of physician practices across 28 specialties, with significant price increases observed post acquisition in dermatology, gastroenterology, and ophthalmology. AMA workforce data and CMS Medicare Provider Enrollment files confirm the platform concentration in each segment.

USAP, the platform at the center of the FTC case, was assembled by Welsh Carson starting in 2012 through more than a dozen acquisitions across Texas, Colorado, Florida, and the Pacific Northwest. NorthStar Anesthesia, backed by Sterling Partners, runs a parallel national platform. In dermatology, US Dermatology Partners and Forefront Dermatology each operate over 100 clinics. In gastroenterology, GI Alliance and US Digestive Health serve as the two leading multistate platforms. Ophthalmology platforms include EyeCare Partners and Acuity Eye Group. Cardiology has accelerated since 2021 with Cardiovascular Associates of America and US Heart and Vascular. Urology consolidation runs through US Urology Partners and Solaris Health. Each platform has executed dozens of tuck in acquisitions and now sits inside the HSR ownership disclosure regime.

Envision, Steward, and the LBO break point #

KKR took Envision Healthcare private in 2018 for roughly 9.9 billion dollars including debt, one of the largest healthcare LBOs on record. Envision filed chapter 11 on May 15, 2023, with about 7 billion dollars of debt transferred to lenders. The No Surprises Act, effective January 1, 2022, capped balance billing for out of network emergency and anesthesia services that had supplied a meaningful share of Envision profitability. UnitedHealthcare in network disputes reduced realized rates further. KKR equity was wiped out and the platform emerged in late 2023 split into AMSURG and a slimmer Envision physician services entity owned by lenders.

Steward Health Care, majority owned by Cerberus from 2010 to 2020 and physician controlled thereafter, filed chapter 11 on May 6, 2024. The bankruptcy schedules listed approximately 9 billion dollars in liabilities, including 6.6 billion dollars of long term lease obligations to Medical Properties Trust, the publicly traded REIT that financed Stewards expansion. The docket showed 31 acute care hospitals across eight states. Senate Finance Committee investigations in 2024 documented sale leaseback transactions in the late 2010s that paid out approximately 800 million dollars to physician owners and Cerberus while leaving Steward with rent obligations the operating cash flow could not service.

These two cases reset assumptions about LBO durability in healthcare services. Both involved 6 to 8 times EBITDA leverage at entry, platforms exposed to payer pricing risk, and sponsor exits that depended on multiple expansion. By 2026, lenders are pricing regulatory and reimbursement risk explicitly, especially for platforms with significant Medicare or Medicaid exposure.

FTC, DOJ, and state enforcement #

The September 21, 2023 FTC complaint against US Anesthesia Partners and Welsh Carson alleged a 13 year strategy to consolidate Texas anesthesia practices, raise prices, and enter price setting agreements with competitors. The complaint named Welsh Carson as the originator and continuing controller of the strategy, even at minority post acquisition stakes. The Welsh Carson defendant was dismissed in May 2024 by the Southern District of Texas, but the case against USAP itself proceeded, and the theory of holding sponsors accountable for rollup conduct survived as a litigation tool. Roark Capital has been the subject of related preliminary review.

The FTC, DOJ, and HHS launched a joint cross government inquiry into private equity in healthcare in March 2024, requesting public comment on rollups, sale leasebacks, and staffing model changes. The Hart Scott Rodino final rule, issued October 10, 2024, and effective February 10, 2025, expanded premerger filings to require disclosure of officers and directors of the acquiring entity, prior acquisitions in overlapping codes within five years, and minority investor relationships. The change forces sponsors to map every adjacent platform inside HSR thresholds. The DOJ Antitrust Division has parallel non public investigations into anesthesia, emergency medicine, and dermatology rollups according to 2024 and 2025 updates.

States moved faster than Washington. California AB 3129, signed by Governor Newsom on September 28, 2024, created a mandatory notice and review framework with discretionary disapproval over PE healthcare transactions. Oregon SB 951, signed in 2024, restricts the corporate practice of medicine and limits non clinical control. Massachusetts H 5159, enacted January 2025 in response to Steward, requires expanded transaction notice, financial disclosure, and Department of Public Health review. Indiana SB 9, New York Article 45 A amendments, and bills in Connecticut, Washington, Pennsylvania, and Illinois sit on the same template.

Hospital pressure, payer verticals, and the 2026 refi wall #

Hospital M and A continued at a slower pace than the prior decade. Kaufman Hall counted 72 announced hospital and health system transactions in 2024, with average target size near 1 billion dollars in revenue, the highest annual average on record. HCA Healthcare divested several smaller community hospitals in 2024 and 2025 while expanding ambulatory capacity in growth markets. Tenet Healthcare divested 14 hospitals between 2022 and 2024 to concentrate on USPI ambulatory surgery and Conifer revenue cycle. CommonSpirit Health reported a fiscal year 2024 operating loss near 1.2 billion dollars on 35 billion dollars in revenue. Ascension reported a fiscal year 2024 operating loss near 1.8 billion dollars and divested 10 Michigan hospitals to Henry Ford Health.

The vertical insurer wave has reshaped buyer dynamics. UnitedHealth Group reports roughly 90,000 employed and affiliated physicians inside Optum at year end 2024, the largest physician footprint in the country, built through Surgical Care Affiliates, DaVita Medical, Atrius, ProHealth, and Refresh Mental Health. CVS Health acquired Oak Street Health for 10.6 billion dollars and Signify Health for 8 billion dollars in 2023, embedding primary care and home risk assessment inside Aetna. Cigna Evernorth grew adjacent capacity through MDLive and other provider acquisitions. The vertical buyer typically pays at lower implied multiples than PE because it values lives covered and risk attribution rather than pure EBITDA.

Burnout and churn complicate exits. An AAFP survey reported that roughly half of family physicians employed by PE backed groups have considered leaving within two years, and the AMA 2024 Physician Practice Benchmark Survey reported that the share of physicians in private practice fell to 42.2 percent from 60.1 percent in 2012. The 2026 leveraged finance maturity wall is the binding constraint. Pitchbook LCD data show roughly 80 to 100 billion dollars of healthcare leveraged loan and high yield maturities concentrated in 2025 to 2027 for PE backed issuers. Refinancing at 9 to 12 percent against entry coupons of 5 to 7 percent compresses free cash flow, and several platforms in dermatology, anesthesia, and gastroenterology have already executed amend and extend transactions or distressed exchanges.

Recommendations by buyer #

For sponsors, the 2018 to 2021 rollup playbook needs revision. Underwrite for an HSR disclosure regime that exposes prior tuck ins, plan for state attorney general review in California, Oregon, Massachusetts, and the next ring of states, and avoid leverage stacks above 6 times EBITDA in specialties exposed to payer pricing risk. Build ancillary revenue, ASC, pathology, imaging, intentionally rather than as a residual. Shorten hold expectations to four to five years. For platforms already at the refi wall, evaluate distressed exchange, minority recapitalization, and partial sale to a vertical insurer rather than a forced auction.

For hospital systems, divest non strategic community assets while disciplined buyers are still active, and negotiate with vertical insurers from a position of clinical integration. CommonSpirit and Ascension show that scale alone does not solve operating losses tied to payer mix and capital structure. HCA and Tenet show that disciplined portfolio shaping toward ambulatory and high acuity tertiary preserves margin. The financing window for non profit systems is narrower than for investor owned peers given Moodys and Fitch downgrade pressure documented through 2024 and 2025.

For payers, the cycle is creating a window to acquire physician capacity at compressed multiples from stressed PE platforms. The risk is that the same regulators reviewing PE deals will increase scrutiny of vertical transactions in 2026 and 2027. Treat each transaction as both an asset purchase and a regulatory filing. For physicians, negotiation leverage in 2026 is higher than at any point since the 2018 wave began, given the documented exit intent in PE backed groups and AMA data on private practice rebalancing.

For policy buyers, the priority is a workable definition of materiality across federal and state regimes, an evidence base on price, quality, and access effects beyond the existing Health Affairs studies, and a clear stance on sale leaseback and REIT structures after Steward. The 2026 to 2028 window is the first time federal and state authorities, hospital systems, payers, and sponsors have aligned incentive to set rules that survive the next cycle.

Sources #

• FTC complaint, FTC v US Anesthesia Partners and Welsh Carson, September 21 2023
• FTC, DOJ, HHS joint Request for Information on private equity in healthcare, March 5 2024
• FTC final rule on premerger notification (HSR), Federal Register October 10 2024
• DOJ Antitrust Division, healthcare enforcement updates
• Envision Healthcare chapter 11 docket, Southern District of Texas, May 15 2023
• Steward Health Care chapter 11 docket, Southern District of Texas, May 6 2024
• Senate Committee on Finance, report on Steward Health Care, January 2025
• California AB 3129, signed September 28 2024
• Oregon SB 951, 2024 session
• Massachusetts H 5159, signed January 8 2025
• Singh, Song, Polsky, Health Affairs, prices and spending after PE acquisition of physician practices, 2022
• AMA 2024 Physician Practice Benchmark Survey
• Pitchbook 2024 Annual Healthcare Services Report
• Kaufman Hall 2024 Hospital M and A Year in Review
• MedPAC March 2025 Report to Congress on Medicare Payment Policy
• CMS Medicare Provider Enrollment, Chain, and Ownership System (PECOS)
• KFF analysis of private equity in healthcare
• AHRQ Compendium of US Health Systems
• BLS Quarterly Census of Employment and Wages, healthcare and social assistance NAICS 62
• ProPublica reporting on Steward Health Care and PE in healthcare
• UnitedHealth Group 2024 Form 10-K, Optum Health physician footprint
• CVS Health 2023 Form 10-K, Oak Street and Signify acquisitions
• AAFP physician survey on private equity ownership